Testosterone, acting as a systemic and local factor, is one of the major regulatory molecules that initiate and maintain testicular function. In the present study, different experimental approaches were used to evaluate the role of testosterone in regulation of the nitric oxide (NO)-cGMP pathway in Leydig cells derived from normal and hypogonadotropic male rats treated with testosterone for 24 h and 2 wk. Real-time quantitative PCR and Western blot analysis revealed increased inducible NO synthase (NOS2) expression followed by increased NO secretion from Leydig cells ex vivo after continuous treatment with testosterone for 2 wk in vivo. The cGMP-specific phosphodiesterases Pde5, Pde6, and Pde9 were up-regulated, whereas PRKG1 protein was decreased after a 2-wk testosterone treatment. Induction of Nos2 and Pde5 in Leydig cells was blocked by androgen receptor antagonist. In experimental hypogonadotropic hypogonadism, expression of NOS2 was significantly reduced, and treatment with testosterone increased NOS2 expression above control levels. PDE5 protein level was unchanged in hypogonadal rats, whereas treatment of hypogonadal rats with testosterone significantly increased it. In contrast, hypogonadism and testosterone replacement reduced PRKG1 protein in Leydig cells.
INTRODUCTION
Illicit use of androgens by younger men and athletes is a growing problem [1, 2] . However, a lack of fundamental knowledge regarding the actions of sex hormones on steroidproducing cells, such as Leydig cells, hampers our ability to understand the short-and long-term consequences of androgen use.
Testicular nitric oxide (NO) signaling pathway is involved in regulation of Leydig cell steroidogenesis [3] [4] [5] [6] [7] [8] [9] [10] [11] . In Leydig cells, NO is produced by NO synthases (NOS) that exists in three isoforms: endothelial (NOS3), neural (NOS1), and inducible (NOS2) [4, 5] . NO potently reduces testosterone production in vivo [6] and, at higher concentrations, directly suppresses Leydig cells function in vitro [7] by inhibition of the heme-containing steroidogenic enzymes CYP11A1 (also known as cytochrome P-450 side-chain cleavage) [7, 8] and CYP17A1 (also known as P450c17) [9] . At low concentrations, NO stimulates Leydig cell steroidogenesis by activating soluble guanylate cyclase (GUCY1; also known as sGC)-cGMP signaling [5, 10] , presumably because of activation of cGMP-dependent protein kinase (PKG; official symbol PRKG) and phosphorylation of steroidogenic acute regulatory (STAR) protein [5, 12] . The signal is terminated by phosphodiesterases (PDEs) [13] and active transport systems that export cyclic nucleotides (multidrug-resistance proteins) from the cell [14] .
On the other hand, little is known about the involvement of testosterone in regulation of NO-cGMP signaling in testosterone-producing Leydig cells. Evidence exists supporting an association between testosterone and NO-cGMP signaling in vascular cells systems [15] . Supraphysiological testosterone levels have a direct vasodilator effect on coronary circulation [16] , and dehydroepiandrosterone up-regulates GUCY1 and inhibits hypoxic pulmonary hypertension [17] . Additionally, testosterone could mediate inflammatory processes, and dihydrotestosterone (DHT) could increase cerebrovascular inflammation through induction of NFkappaB, NOS2, and cyclooxygenase-2 [18, 19] . At physiological levels, testosterone and DHT enhance apoptotic damage in human vascular endothelial cells [15] . Also, PDE5 expression is positively regulated by androgens in male reproductive tract [20, 21] .
Previously published findings in different cell types suggest that androgens could exert a regulatory role on NO signaling, but how testosterone affects NO-cGMP signaling in testosterone-producing Leydig cells is unknown. The present study was designed to address the hypothesis that high levels of testosterone regulate the NO-cGMP signaling pathway in Leydig cells. We utilized four different experimental approaches: three in vivo studies (in vivo treatment with testosterone enanthate, an experimental model of hypogonadotropic hypogonadism together with testosterone replacement, and treatment with androgen receptor antagonist) and one in vitro study of the effects of testosterone on purified Leydig cells.
MATERIALS AND METHODS

Materials
The purified rabbit polyclonal antibody against PDE5 was a generous gift from Prof. Sergei Rybalkin. Commercial purified rabbit polyclonal antibody against PDE5 and purified rabbit polyclonal antibody recognizing the type Ia-/ Ib-isoforms of PRKG (PKG) were obtained from Calbiochem. Antibody against NOS2 was from Transduction Laboratories, b-actin detection kit was from Oncogene Research Product, and the anti-mouse and anti-rabbit secondary antibodies linked to horseradish peroxidase were from Kirkegaard & Perry Laboratories. The anti-testosterone-11/bovine serum albumin (BSA) serum ( 
Animals and In Vivo Treatment
Adult (age, 3 mo; body wt, 250-270 g) male Wistar rats, bred and raised in the Animal Facility of the Department of Biology and Ecology (Faculty of Sciences, University of Novi Sad), were used for the experiments. The animals were raised in controlled environmental conditions (22 6 28C; 12L:12D, lights-on at 0700 h) with food and water ad libitum.
To mimic to the most likely route of human exposure, three in vivo experimental approaches with testosterone-enanthate were applied: 1) treatment of intact male rats with testosterone enanthate (ab)used as an androgen anabolic steroid and contraceptive drug [22] , 2) experimental model of testosterone enanthate replacement therapy for hypogonadal animals [20] , and 3) blockade of testosterone enanthate effect with application of Androcur, a potent androgen receptor antagonist.
In the first experimental approach, adult male rats were divided into three groups of eight rats each: 1) control, 2) treatment with a single intramuscular injection of testosterone enanthate (0.577 mg per 50 ll per 100 g body wt) for 1 day, and 3) treatment with a weekly intramuscular injection of testosterone enanthate for two weeks. The mean half-life estimates of the terminal elimination phase is approximately 7 days in orchidectomized cynomolgus monkeys [23] . Because both experimental groups were treated with intramuscular injections of testosterone enanthate dissolved in olive oil, rats in the control group received only olive oil (50 ll/100 g body weight). Each experiment was repeated three times.
In the second experimental approach, we used a model of induced hypogonadotropic hypogonadism and replacement treatment with testosterone enanthate following the induction of hypogonadism [20] . Adult male rats were divided into four groups of five rats each: 1) control; 2) rats injected with the long-lasting GnRH analog triptorelin (0.29 mg/100 g); 3) rats injected with triptorelin and, after 2 wk, treated with testosterone enanthate (2.5 mg/100 g weekly for 2 wk); and 4) rats receiving testosterone enanthate (2.5 mg/100 g weekly for 2 wk). The experimental hypogonadism and sex steroid replacement model experiment was repeated four times.
In the third experimental approach, we blocked androgen receptor using Androcur. Adult male rats were divided into four groups of six rats each: 1) control; 2) rats receiving testosterone enanthate (0.57 mg/100 g weekly for 2 wk); 3) rats injected with the androgen receptor antagonist, Androcur (0.4 mg/ 100 g weekly for 2 wk); and 4) rats injected with both Androcur (0.4 mg/100 g weekly for 2 wk) and testosterone enanthate (0.57 mg/100 g weekly for 2 wk). Because treated rats received intramuscular injections of steroid dissolved in ricinus seed oil, rats in the control group received only ricinus oil.
At the end of experimental period in all experiments, all groups were quickly decapitated. Serum was collected, with individual serum samples stored at À208C until assaying for LH and androgens (testosterone plus DHT [TþDHT]), and ex vivo experiments were performed.
Preparation of Purified Leydig Cell and Hormone and Messenger Production
To follow ex vivo steroidogenesis and the production of messengers related to the NO-cGMP signaling pathway, we used primary cultures of purified Leydig cells obtained from control and experimental rats.
Primary cultures of purified Leydig cells were prepared from suspensions of interstitial cells as previously described by our group [5, 24] . Suspensions of interstitial cells were prepared according to Anakwe et al. [25] with some modifications as described previously by our group [5, 24] . Testes were quickly removed, decapsulated, and placed in a 50-ml plastic tube (two testes per tube) containing 3 ml of collagenase solution (1.2 mg/ml of collagenase type IA, 1.5% BSA, and 20 mM Hepes in DMEM/F12) and incubated for 15 min at 348C in a shaking water bath oscillating at 120 cycles/min. The dissociated cells were diluted in 20 ml of cold M199-0.5% BSA and placed on ice for 5 min to allow the seminiferous tubules to settle before filtering the supernatant through Mesh (product No. 100; Sigma). The resulting cell suspension was centrifuged at 160 3 g for 5 min at room temperature, and then the cell pellet was washed twice in M199-0.5% BSA and resuspended in a corresponding amount (5 ml/testis) of DMEM/F12-0.1% BSA. The 0.2% trypan blue dye exclusion test (Sigma) was used to determine total cell counts and to ensure that more than 95% of the cells were viable. This suspension of interstitial cells was used to prepare primary cultures of purified Leydig cells [5, 24] by centrifugation on a Percoll gradient consisting of four 2-ml layers of Percoll with densities of 1.090, 1.080, 1.065, and 1.045 g/ml (formed by mixing isotonic Percoll consisting of 103 concentrated DMEM/F12 enriched with 3% BSA and the corresponding amount of Percoll and distilled water). A crude suspension of interstitial cells (;35-40 3 10 6 cells) was applied to each Percoll gradient and centrifuged at 500 3 g for 28 min at room temperature. Fractions containing Leydig cells were collected from the 1.080/1.065-g/ml and 1.065/ 1.045-g/ml interfaces, washed in 50 ml of M199-0.1% BSA, and centrifuged at 200 3 g for 5 min at room temperature. The cells were resuspended in a corresponding amount (2.5 ml/testis) of culture medium (DMEM/F12 supplemented with 100 IU/ml of penicillin and 100 lg/ml of streptomycin) and counted. The proportion of Leydig cells present in culture was determined by staining for 3b-hydroxysteroid dehydrogenase activity [26] and found to be 96.8% 6 1.1%, whereas the viability was more than 90%. The steroidogenic capacity of Leydig cells (estimated by dose-dependent stimulation with human chorionic gonadotropin) and the activity of steroidogenic enzymes (estimated by incubating cells with increasing concentrations of steroid substrates) were in line with those previously published by others [27] and by our own group [5, 24] . Purified Leydig cells obtained individually from five to eight rats were pooled and plated in 90-mm Petri dishes (5 3 10 6 cells per 5 ml of culture medium per dish). Three to five replicates of each pool/group were cultured and placed in to the CO 2 incubator (348C) for 3 h to attach and recover. At the end of the recovery period, the culture medium was discarded, and cells were incubated with M199-0.1% BSA or with media supplemented with 100 lM of L-arginine (NOS substrate) and/or with 1 mM Ag (NOS2 inhibitor). After 2 h, cell-free medium was collected and stored at À808C before the measurement of nitrite and androgen levels, whereas cGMP was measured in terms of cell content. For experiments also measuring levels of transcripts (real-time PCR analysis) and proteins (Western blot), purified Leydig cell lysates were used as a source of RNA or protein.
For in vitro experiments, purified Leydig cells (5 3 10 6 cells per 5 ml of culture medium per dish) obtained from normal rats were incubated with physiological concentrations of testosterone (0, 1, 10, and 20 lM) for 20 h. After 20 h, cells were washed and incubated for another 2 h in fresh medium. At the end of incubation, medium was picked up and used for hormone and nitrite production, whereas cells were used for cGMP measurement in the cell content for RQ-PCR analysis.
Hormone, Nitrite, and cGMP Measurement
Progesterone, testosterone, and LH levels were measured by RIA [5, 24] . Levels of androgens are referred to as TþDHT, because the anti-testosterone serum (product No. 250) showed 100% cross-reactivity with DHT [5, 24] . All samples from each experiment were run in one assay (sensitivity, 6 pg/tube; TESTOSTERONE MODULATES NO SIGNALING IN LEYDIG CELL 435 intra-and interassay coefficients of variation, 5-8% and 7.5%, respectively). Serum LH level was measured by RIA according to the manufacturer's protocol (Rat LH RIA Kit; ALPCO Diagnostics); the minimum detectable concentration has been assayed at 0.14 ng/ml (intra-and interassay coefficients of variation, 8-12% and 7-22%, respectively). Level of cGMP was measured by the cGMP EIA kit, which typically permits cGMP measurement with a limit of quantification of 0.07 pmol/ml (at 80% of standard bound/maximum bound) for acetylated cGMP samples [5] . Cyclic GMP was extracted from scraped cell content by ethanol using a procedure described previously [28] . For measurement of nitrite levels in the medium, sample aliquots were mixed with an equal volume of Griess reagent, and the absorbance was measured at 546 nm [29] . Nitrite concentrations were determined relative to a standard curve derived from increasing concentrations of sodium nitrite [5] .
RNA Isolation and cDNA Synthesis
Total RNA from purified rat Leydig cells was isolated using RNeasy kit reagent (Qiagen) following a protocol recommended by the manufacturer. Total RNA concentration and purity were determined spectrophotometrically. To eliminate residual genomic DNA, RNA samples (2 lg of total RNA) were treated with 2 IU of DNase-I in a 20-ll reaction mixture. Following DNase-I treatment, first-strand cDNA was synthesized in duplicate reactions for each RNA sample. Next, 2 lg of total RNA from each sample were reverse transcribed into cDNA in a 20-ll reaction mixture containing oligo-(dT)18 primer and Superscript III reverse transcriptase (Invitrogen) according to the manufacturer's instructions. Negative controls consisting of non-reversetranscribed samples were included in each set of reactions. RNA quality and DNA integrity were checked using primers for RS16 and glyceraldehyde 3-phosphate dehydrogenase.
Real-Time PCR and Relative Quantification Using SYBR Green
The relative expression of the genes for NO-cGMP signaling pathway elements [30] was quantitated by real-time PCR [31] using SYBR Green for amplicon detection and ROX (25 lM solution of 5-carboxy-X-rhodamine in 10 mM Tris-HCI (pH 8.6), 0.1 mM EDTA, and 0.01% Tween-20) as an internal reference dye. Standard PCR settings (508C for 2 min, 958C for 10 min, and 40 cycles of 958C for 15 sec and 608C for 1 min) were used in an ABI Prism 7900HT Sequence Detection System (Applied Biosystems) in the presence of 500 nM specific forward (F) and reverse (R) primers and 5 ll of product from reverse transcription reaction (23 diluted). The primers were design by using Primer Express 3.0 (Applied Biosystems) and full gene seqences from the National Center for Biotechnology Information Entrez Nucleotide database (www.ncbi.nlm.nih.gov/sites/entrez). The primer sequences used for real-time PCR analysis were as follows: Nos1 (GenBank accession no. NM_052799: F,
, and Actb (GenBank accession no. NM_031144; F, 5 0 -TTCAACACCCCAGCCATGT-3 0 ; R, 5 0 -TGGTACGAC CAGAGGCATACAG-3 0 ). Actb mRNA was also measured in the same samples and used to correct variations in RNA content among samples. The relative quantification of gene expression for NO-cGMP signaling pathway elements was calculated using ABI Prism 7900HT sequence detection system software and Relative Quantification Manager software (Applied Biosystems). Relative quantification of each gene was done in duplicate, twice for each of three independent in vivo experiments.
Real-Time PCR and Relative Quantification Using TaqMan Low Density Rat PDE Panel
The expression of the genes for PDEs in Leydig cells obtained from control and experimental rats was analyzed in relative quantification real-time RQ-PCR using the TaqMan Low Density Rat PDE Panel Assay and ABI Prism 7900HT Sequence Detection System and Relative Quantification Manager [30] . Actb was used as an endogenous control and quantitated in the same real-time PCR as a part of TaqMan Low Density Rat PDE Panel, then used to correct for variations in RNA content among samples (30 ng of sample per port were used). Each sample was run in duplicate or triplicate, three times for each gene, for each of three independent in vivo experiments.
Western Blot Analysis
After incubation, Leydig cells (5 3 10 6 cells/well) were washed twice with ice-cold PBS and lysed in 1 ml of buffer containing 20 mM Hepes, 10 mM EDTA, 40 mM b-glycerophosphate, 1% tergitol, 2.5 mM MgCl 2 , 1 mM dithiothreitol, 0.5 mM 4-(aminoethyl)-benzenesulfonyl fluoride hydrochloride, 20 lg/ml of aprotinin, 20 lg/ml of leupeptin, and a cocktail of phosphatase inhibitors (0.05 mM (À)-P-bromotetramisol oxalate, 10 lM cantharidin, and 10 FIG. 1. Serum hormone levels and hormone/messenger production by Leydig cells isolated from testosterone-treated or control rats. Rats were treated with intramuscular injections of Testosterone Depot (0.577 mg/100 g, weekly) and killed 1 day later (T-1d) or 1 wk after the second injection (T-2ws). Trunk blood was collected, and serum LH (A) and TþDHT (B) levels were determined by RIA. Primary cultures of purified Leydig cells (5 3 10 6 cells/well) were incubated for 2 h, and TþDHT (C) and nitrite (D) accumulation were determined in incubation medium while cells were scraped and used for cGMP determination (E). Data bars represent the group mean 6 SEM of three to five independent experiments. Statistical significance between controls and experimental groups: *P , 0.05.
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nM microcystin-LR; pH 7.5) [5, 24] . Protein concentrations were estimated by the Bradford method using BSA as a standard [32] .
For Western blot analysis, an equal amount of cell lysate proteins (1:1, v/v) was mixed with the SDS-PAGE loading buffer, denatured for 5 min at 958C, and loaded on SDS-PAGE 16% gels. All gels were analyzed by onedimensional SDS-PAGE using a discontinuous buffer system, and proteins were transferred to a polyvinylidene fluoride membrane (Immobilon-P; Millipore) using a wet transfer according to the manufacturer's recommendation. The immunodetection of NOS2 was performed using purified anti-mouse antibody against NOS2 (Transduction Laboratory) at a dilution of 1:1000, whereas PDE5 was detected with purified rabbit polyclonal antibody against PDE5 (one part of the experiments was done with antibody kindly provided by Prof. Sergei Rybalkin [33] , whereas the others were done with commercial antibody obtained from Calbiochem [dilution, 1:1000]). The PRKG1 was detected using rabbit polyclonal antibody recognizing type Ia-and Ib-isoforms of PRKG (PKG) (dilution, 1:1000; Calbiochem), whereas b-actin was detected by using b-actin detection kit (dilution, 1:5000; Oncogene Research Product). The reactive bands were always determined with a luminol-based kit (Pierce), and the reaction was detected by an enhanced chemiluminescence system using x-ray film. The immunoreactive bands were analyzed as two-dimensional images using Image J (version 1.32; www.rsb.info.nih.gov/ij/download.html). The optical density of images is expressed as volume (optical density 3 area) adjusted for the background, which gives arbitrary units of adjusted volume.
Statistical Analysis
For in vivo studies, results are shown are the group mean 6 SEM from three to four independent experiments (n ¼ 5-8 rats per group per experiment). For in vitro studies, data represent the mean 6 SEM from three to five independent experiments. Each of three to five independent experiments was run on pools of Leydig cells cultured in four to six replicates. The average of the results from each experiment was analyzed by Mann-Whitney unpaired nonparametric two-tailed test (for two-point data experiments) or, for group comparison, a one-way ANOVA followed by Student-Newman-Keuls multiple-range test.
RESULTS
Effects of In Vivo Testosterone Treatment on NO-cGMP Signaling Pathway and Androgen Production in Leydig Cells
In adult male rats, intramuscular injections of testosterone enanthate for 1 day or 2 wk caused significantly decreased serum LH (Fig. 1A) and significantly elevated serum TþDHT (Fig. 1B) . Steroidogenic activity of purified Leydig cells obtained from rats after in vivo treatment with testosterone enanthate was unchanged after 1 day of treatment but
FIG. 2. Testosterone treatment affects expression of NO-cGMP signaling pathway elements in Leydig cells. A)
Quantitative gene expression of Nos3, Nos2, Gucy1a1, Gucy1b1, Prkg1, and Pde5. PCR reactions were performed by SYBR Green technology in presence of specific primers (see Materials and Methods). B and C) Quantitative gene expression of cGMP-specific (B) and dual-specific (C) Pde genes (Pdes). RQ-PCR analysis was performed by TaqMan technology using TaqMan Low Density Rat Phosphodiesterase Panel. D-F) Western blot analysis for NOS2, PRKG1, and PDE5. Leydig cells lysates isolated from control and testosterone-treated rats were subjected to SDS-PAGE electrophoresis, followed by Western blots for either NOS2 (D), PRKG1 (E), or PDE5 (F). b-Actin was used as internal control and is presented below the blots. A representative blot is shown in each panel, whereas pooled data from scanning densitometry normalized to b-actin values are shown as bars above the blots and represent the mean 6 SEM for three independent experiments. T-1d, 1 day of testosterone treatment; T-2ws, 2 wks of testosterone treatment. Statistical significance between controls and testosterone treated groups: *P , 0.05.
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significantly decreased after 2 wk of exposure to testosterone enanthate (Fig. 1C) . The production of NO from purified Leydig cells of androgenized animals was unchanged after 1 day of treatment but significantly increased during 2 wk of exposure to testosterone enanthate (Fig. 1D) . Production of cGMP by purified Leydig cells from androgenized animals remained unchanged in comparison to controls (Fig. 1E) .
Expression of specific components of the NO-cGMP signaling pathway was analyzed by extracting mRNA from purified Leydig cells obtained from controls and androgenized male rats. Gene and protein expression levels were accessed by RQ-PCR and Western blot, respectively. RQ-PCR analysis revealed that Nos2 expression was increased after 2 wk of testosterone treatment, whereas Nos3 was not significantly changed ( Fig. 2A) . Expression of Nos1 transcript was below the detectable level (cycle threshold . 30 cycles), so it was omitted from the present work. Testosterone treatment did not affect expression of Gucy1a1 and Gucy1b1 subunits and of Prkg1 (Fig. 2A) . Also, 2 wk of testosterone treatment significantly enhanced expression of Pde genes responsible for cGMP degradation in adult rat Leydig cells: Pde5, Pde6d, and Pde9a (Fig. 2, A and B) . Expression of Pde5 and Pde9a was also affected 1 day after treatment. Additionally, 2 wk of testosterone treatment stimulated expression of dual-specific Pde genes, Pde1c and Pde3a, whereas Pde10a was significantly augmented only after 1 day of testosterone treatment (Fig. 2B) .
Western blot analysis confirmed the stimulatory effect of 2 wk of testosterone treatment on NOS2 and PDE5 protein expression in Leydig cells (Fig. 2, C and F) . In contrast, PRKG1 protein level was dramatically decreased in Leydig cells obtained from rats treated for 1 day and 2 wk with testosterone (Fig. 2D) .
Effects of Experimental Hypogonadotropic Hypogonadism and Testosterone Replacement Treatment on NO-cGMP Signaling Pathway and Androgen Production in Leydig Cells
Experimental hypogonadotropic hypogonadism was induced by treatment of adult male rats with the long-lasting GnRH analog triptorelin. After 2 wk, triptorelin-treated rats as well as vehicle-treated rats were supplemented weekly with testosterone enanthate for 2 wk. Triptorelin treatment significantly decreased serum LH levels (Fig. 3A) and abolished serum testosterone levels (Fig. 3B) and testosterone production by Leydig cells (Fig. 3C) . Additionally, Leydig cell nitrite production was decreased in hypogonadal rats and increased in both testosterone-treated group of rats (Fig. 3D) . The cGMP production was reduced by all treatments (Fig. 3E) . Because testosterone withdrawal or supplementation affected messenger production by Leydig cells, an expression analysis of NOcGMP pathway elements was performed. The Nos2 gene expression was up-regulated following testosterone treatment but inhibited in Leydig cells isolated from hypogonadal animals. Testosterone replacement restored Nos2 transcript levels slightly above control values (Fig. 4A) . The NOS2 protein levels mirrored the mRNA quantitative values (Fig.  4C) , suggesting the involvement of testosterone in the regulation of NOS2 expression. The status of cGMP-specific PDEs was also affected by hypogonadism and/or testosterone treatment. The expression of Pde5 was not changed in hypogonadal rats but was significantly increased following testosterone treatment in hypogonadal and normal rats (Fig. 4,  A and B) . Western blot analysis confirmed the stimulatory effect of testosterone treatment on PDE5 protein levels in Leydig cells derived from normal as well as hypogonadal rats, whereas hypogonadism did not affect PDE5 protein expression (Fig. 4E ). In accord with our results shown in Figure 2B , the expression of Pde6d and of Pde9a was increased by testosterone administration, whereas hypogonadism decreased Pde6d and Pde9a transcript levels in Leydig cells (Fig. 4B) . These effects were not reversed by testosterone substitution (Fig. 4B) . Furthermore, Prkg1 mRNA and protein levels in Leydig cells derived from hypogonadal rats were significantly lower than those in controls (Fig. 4, A and D) . Testosterone treatment of both hypogonadal and normal rats slightly decreased Prkg1 mRNA level (Fig. 4A) and significantly   FIG. 3 . Serum hormone levels and hormone/messenger production by Leydig cells isolated from hypogonadal and testosterone-treated (T) rats. Rats were treated with single injection of triptorelin (0.29 mg/100 g) or vehicle. After 2 wk, another group of rats as well as a triptorelin-treated group received testosterone (2.5 mg/100 g weekly for 2 wk). Four weeks after triptorelin injection and 1 wk after the last testosterone injection, rats were killed, trunk blood was collected, and serum LH (A) and TþDHT (B) levels were determined by RIA. Primary culture of purified Leydig cells (5 3 10 6 cells/well), isolated from control or experimental rats, were incubated for 2 h, and TþDHT (C) and nitrite (D) accumulation in the medium were measured while cells were scraped and cGMP extracted and measured by RIA (E). Data bars represent the group mean 6 SEM of three independent experiments. Statistical significance between controls and experimental groups: *P , 0.05.
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reduced PRKG1 protein level (Fig. 4D) in Leydig cells. Under the same experimental conditions, expression of Gucy1a1 and Gucy1b1 subunits of GUCY1 was not affected (Fig. 4A) .
Effects of Androgen Receptor Antagonist on NO-cGMP Signaling Pathway and Androgen Production in Leydig Cells from Androgenized Male Rats
To investigate whether the observed testosterone effects are, indeed, androgen related, rats were treated with androgen receptor antagonist (Androcur) weekly for 2 wk, either alone or in combination with testosterone. Treatment with Androcur increased serum LH level, whereas the combination of Androcur plus testosterone prevented the LH decrease observed in androgenized rats (Fig. 5A) . Serum testosterone level was increased following Androcur-only and testosteroneonly treatment as well as in combination treatment (Fig. 5B) . Treatment with androgen receptor antagonist prevented the decline of ex vivo testosterone production observed in androgenized rats (Fig. 5C) . Moreover, blockade of androgen receptor decreased Leydig cell NO production, whereas in cells from animals treated with the combination, NO production was normalized compared to that in androgenized rats (Fig. 5D) . Androcur treatment decreased Nos2 expression and effectively blocked Nos2 and Pde5 induction following testosterone treatment (Fig. 5E) . Androcur treatment did not change Gucy1a1 and Gucy1b1 as well as Prkg1 expression (Fig. 5E ).
Because testosterone treatment induced NOS2 expression, increased nitrite formation, and decreased testosterone production from isolated Leydig cells, we tried to establish some functional link between the observed changes. Primary cultures of Leydig cells obtained from testosterone-treated, Androcurtreated, or combination-treated rats were exposed ex vivo to LArg (NOS substrate) and/or Ag (NOS2 inhibitor). Results showed that ex vivo stimulation of NOS signaling additionally increased accumulation of nitrite in incubation media of Leydig cells obtained from androgenized rats, but that this effect was abolished with Androcur treatment (Fig. 5D) . Under the same experimental conditions, androgen production in Leydig cells from rats treated with testosterone was additionally decreased, but this was normalized with Androcur treatment (Fig. 5C) . Moreover, inhibition of NOS2 signaling with Ag decreased nitrite accumulation (Fig. 5D ) and increased androgen production (Fig. 5C ) in culture media of Leydig cells from testosterone-treated rats. Moreover, ex vivo treatment of Leydig cells from the androgenized group with NOS2 inhibitor additionally increased androgen production compared to untreated cells of the same group of rats (Fig. 5C) . The existence of a significant negative correlation between nitrite and androgen secretion following testosterone treatment (R ¼ À0.90, P , 0.05 in the testosterone-treated group vs. R ¼ À0. 19 , not significant in the control group) indicate the involvement of NO signaling in down-regulation of androgen production in Leydig cells from androgenized rats .   FIG. 4 . Experimental hypogonadism and testosterone replacement (T) affects the expression of NO-cGMP signaling pathway elements in Leydig cells. A) Quantitative gene expression of Nos3, Nos2, Gucy1a1, Gucy1b1, Prkg1, and Pde5. PCR reactions were performed by SYBR Green technology in presence of specific primers (see Material and Methods). B) Quantitative gene expression of cGMP-specific Pde genes (Pdes). RQ-PCR analysis was performed with the TaqMan Low Density Rat Phosphodiesterase Panel. C-E) Western blot analysis for NOS2, PRKG1, and PDE5. Leydig cells lysates isolated from control and treated rats were subjected to SDS-PAGE electrophoresis, followed by Western blots for either NOS2 (C), PRKG1 (D), or PDE5 (E). b-Actin was used as internal control and is presented below the blots. A representative blot is shown in each panel, whereas pooled data from scanning densitometry normalized on b-actin values are shown as bars above the blots. Data bars represent the mean 6 SEM for three independent experiments. Statistical significance between controls and treated groups: *P , 0.05.
Effects of In Vitro Testosterone on Nos2 Gene Expression in Purified Leydig Cells
To evaluate the direct influence of testosterone treatment on Leydig cell NO-cGMP signaling, in vitro experiments were performed. Our results clearly showed that adding testosterone to the culture medium gradually increased Nos2 gene expression (Fig. 6A) followed by increased production of nitrite (Fig. 6B ) and, consequently, cGMP (Fig. 6C) by Leydig cells. Contrary to the in vivo testosterone paradigm, Pde5 expression was not changed with any investigated testosterone concentration (Fig. 6A) . Lastly, in vitro testosterone addition to the culture medium did not change expression of the Gucy1a1, Gucy1b1, and Prkg1 genes (Fig. 6A) .
DISCUSSION
The data obtained in our study provide novel evidence for the role of testosterone in the down-regulation of Leydig cell steroidogenesis by regulating the NO-cGMP signaling pathway. Prolonged treatment of intact rats with testosterone enanthate caused significant decreases in serum LH, and it significantly reduced the capacity of purified Leydig cells to produce testosterone ex vivo. In these animals, NOS2 protein level and NO production were significantly up-regulated. These effects were abolished by in vivo application of a potent androgen receptor blocker. In hypogonadal animals with low serum testosterone, the NOS2 protein level and NO production from purified Leydig cells ex vivo were significantly reduced. Furthermore, our in vitro results indicate that testosterone gradually up-regulated Nos2 gene expression and NO production in primary Leydig cell cultures. These findings suggest that up-regulation of Nos2 gene expression is a direct effect of testosterone on Leydig cells.
In androgen-producing Leydig cells, the NO-cGMP signaling pathway participates in the regulation of steroidogenic activity [5] . NO potently reduces testosterone production in vivo [6] and, at higher concentrations, directly suppresses Leydig cells function in vitro [7] by inhibiting the hemecontaining steroidogenic enzymes CYP11A1 (also known as cytochrome P-450 side-chain cleavage) [7, 8] and CYP17A1 (also known as P450c17) [9] . On the contrary, at low concentrations, NO stimulates Leydig cells steroidogenesis by activating GUCY1-cGMP signaling, presumably as a consequence from activation of PRKG1 and phosphorylation of STAR protein [5] . 
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The expression of Nos2 mRNA and protein was consistently found in purified rat Leydig cells, indicating its constitutive expression [34] . Up-regulation of NOS2 expression and increased NO production following testosterone treatment could contribute significantly to down-regulation of Leydig cell steroidogenesis via direct inhibition of steroidogenic enzymes [7] [8] [9] as well as by interfering with their expression [35] . In line with this, the present results could be connected with decreased Cyp11a1 and Cyp17a1 expression in Leydig cells from androgenized rats (Kostic et al., unpublished results). Furthermore, our experiments support a significant negative correlation between the NO signaling pathway and steroidogenesis in Leydig cells from rats treated with testosterone. In this group, as a consequence of NOS2 induction, ex vivo stimulation of Leydig cell NOS signaling led to decreased testosterone production, and this effect was abolished by NOS2 inhibition. In vivo treatment with the androgen receptor blocker prevented testosterone-evoked NOS2 induction and decrease in testosterone secretion.
The process of NOS2 expression involves different signal transduction pathways, including nuclear translocation of the transcription factor nuclear factor-kappa B (NFKB) [36] . Induction of androgen receptor leads to degradation of NFKB inhibitory protein and stimulation of NFKB-mediated transcriptional activation [37, 38] . In Leydig cells of androgenized rats, expression of androgen receptor was stimulated (Kostic et al., unpublished results), supporting the positive role of Leydig cell androgen receptor in mediating the effect of testosterone on NOS2 induction. Additionally, further evidence indicates that increased NO synthesis through up-regulation of NOS2 plays a major role in the induction of apoptosis in various cell systems [39, 40] . At present, however, it remains unclear whether the excessive testosterone levels also affect total Leydig cell numbers through induction of apoptosis and, thereby, contribute to the testosterone-induced suppression of testicular steroidogenesis.
Both mRNA and protein levels of PDE5 significantly increased in purified Leydig cells after testosterone treatment and were normalized by androgen receptor blockade, suggesting that testosterone may down-regulate steroid production by reducing cGMP production. Therefore, despite NO-induced GUCY1 stimulation following testosterone treatment, increased PDE5 expression and enzymatic activity could prevent the stimulatory action of cGMP on testicular steroidogenesis. In hypogonadal animals, a low level of serum testosterone was sufficient to maintain basal PDE5 production. In contrast, increased testosterone concentrations significantly increased PDE5 expression, suggesting that stimulation of PDE5 expression requires higher testosterone concentrations. The lack of a stimulatory effect of high testosterone concentrations on PDE5 expression in purified Leydig cells in vitro suggests that other systemic hormones as well as an intact microtesticular environment are required for testosterone-dependent PDE5 induction. This observation is in agreement with a recent report that PDE5 expression is not directly under androgen regulation [41] but probably depends on increased NO/cGMP production [42, 43] . Furthermore, a similar expression pattern of NOS2 at two time points, 1 and 14 days of testosterone application, could be correlated with increased PDE5, PDE6D, and PDE9A expression. This up-regulation of PDE6D and PDE9A in Leydig cells isolated from testosterone-treated rats also suggest an active role of other cGMP-specific PDEs in degrading NO-stimulated cGMP.
Slightly reduced levels of Prkg1 mRNA and a significant decrease in its protein content are in agreement with findings that increased NOS2 activity as well as stimulation of NO and/ or cGMP down-regulate PRKG1 expression [44] [45] [46] through transcription factor SP1 [47] . It is conceivable that a high output of NO in response to NOS2 induction suppresses PRKG expression in Leydig cells of testosterone-treated animals. The apparent discrepancy between Prkg1 mRNA and protein expression is probably the result of broad alterations in transcriptional/posttranscriptional and translational/posttranslational processes. Additionally, the increased accumulation of cGMP increases PRKG1 ubiquitination [48] . Unfortunately, the mechanism of PRKG1 down-regulation in Leydig cells isolated from hypogonadal animals in our experimental model remains to be clarified. In our experiments, in vivo testosterone treatment decreased PRKG1 and increased PDE5 expression, leading to attenuation of cGMP stimulatory effects on Leydig cell steroidogenesis.
In the classical pathway, the opposing activities of GUCY1 and PDE and the effect of PRKG on its targets determine the indirect biological responses to NO signaling in Leydig cells. In that respect, our results of increased mRNA and protein PDE5 expression in Leydig cells following in vivo testosterone treatment may contribute to down-regulation of steroidogenesis. In Leydig cells, increased level of cGMP has a stimulatory effect on initiation of steroidogenesis [5, 12] . In case of intensive NO-dependent GUCY1 stimulation, increased PDE5 expression could be the mechanism that abolishes stimulatory action of overproduced cGMP. Our in vivo results are in accordance with those of studies showing positive androgen regulation of PDE5 [20, 21] .
Although Leydig cell steroidogenesis is mainly regulated through the LH receptor [49, 50] , it also requires local paracrine-autocrine factors to maintain and modulate steroidogenesis. Such regulation is a multicompartmental process and includes several endocrine, paracrine, and autocrine signaling pathways (for review, see [51, 52] ). The complexity of this extracellular-intracellular network is a major obstacle to understanding the physiology of testicular function, and our results point to the NO-cGMP signaling pathway, together with LH receptor signaling, as an important regulator of testicular steroidogenesis. The ability of increased testosterone concentrations to up-regulate NO signaling via increased NOS2 expression and down-regulation of cGMP signaling via increased PDE5 and decreased PRKG1 expression in Leydig cells provides evidence that testosterone-induced modulation of NO-cGMP signaling may serve as a potent autocrine regulator of testicular steroidogenesis. In summary, the fact that NO is involved in the physiology, biology, and pathophysiology of the reproductive system may have great clinical implications in developing therapeutic strategies to prevent NO-related reproductive disorders.
